We previously reported that long-acting GnRH analogue therapy can lower testosterone levels and ameliorate hyperandrogenism in patients with primary SIR resulting from insulin receptor autoantibodies (P13; (30)). The gene discussed is GNRH1; the disease is hyperandrogenism.